Form 4: Vir Biotechnology Director Hatfield Acquires Shares and Options

Director Jeffrey S. Hatfield reports acquisition of Vir Biotechnology stock and options, signaling potential confidence in the company's future.

Summary

• On May 30, 2024, Jeffrey S. Hatfield, a director of Vir Biotechnology, Inc., acquired 8,000 shares of common stock at $0 and was granted options to purchase 16,000 shares.
• Following the transaction, Hatfield directly owns 23,806 shares of common stock.
• The stock options have an exercise price of $10.39, are exercisable from May 30, 2025, and expire on May 29, 2034.
• After the transaction, Hatfield directly owns 16,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's acquisition of shares and options, indicating confidence. However, it's a routine filing, so the impact is limited.

Positives

• A director's acquisition of company stock and options can be seen as a positive signal, indicating confidence in the company's prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the director's acquisition suggests a potentially positive outlook.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Stakeholder Impact

• The director's purchase may positively influence shareholder sentiment.

Key Dates